LGND - Ligand Pharmaceuticals Forward P/S Multiple

Corporate company logo of ligand.com (LGND)

The expected P/S ratio reflects the valuation dynamics of Ligand Pharmaceuticals (LGND), with the latest value recorded as 5.20. A stable liquidity surplus driven by royalties minimizes capital expenditures. High return on assets is supported by a diversified patent portfolio. Meanwhile, Ligand Pharmaceuticals relies on outsourcing production and trials, concentrating its resources exclusively on the discovery of promising molecules.

ligand.com - LGND Projected Price to Revenue (period 07/04/2022 - 11/17/2026)

Ligand Pharmaceuticals - analytical breakdowns and key metrics (LGND)

- market price and analyst price targets:
Fundamental company valuation:Ligand Pharma (LGND)
Original product of Ligand Corp

Market expectations for the P/S ratio of Ligand Pharmaceuticals (LGND) reflect a high valuation of its resilience due to a royalty model that eliminates direct commercialization costs. The current value of 5.20 measures the ratio of market capitalization to projected revenue, allowing investors to determine whether the asset is overbought or searching for a price floor within the cyclical range of fundamental value through Ligand Pharmaceuticals (LGND) P/S expectations.

Key competitors

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Projected Revenue Ratio|Perrigo Company PLC - Forward Price to Sales|Price-to-Projected Revenue Ratio alvotech.com|Forward P/S Multiple Liquidia Technologies|Price-to-Projected Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Future Price to Revenue|Forward P/S Multiple MNKD (MannKind Corp)|Market Cap to Expected Sales Ratio Amphastar (AMPH)|PCRX: Forward Price-to-Revenue Multiple|SPRY - Forward P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Projected Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Projected Revenue Ratio|SCPH (scpharmaceuticals.com) - Forward P/S Multiple|TECX: Forward Price to Sales|Price-to-Projected Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Forward Price to Sales BHST|Invizyne Technologies - Forward P/S Multiple|oramed.com (ORMP) - Forward Price-to-Revenue Multiple|ENTX (enterabio.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue HYFT|ABVC (ABVC BioPharma, Inc) - Forward P/S Multiple|Forward P/S Multiple cumberlandpharma.com|Price-to-Projected Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Projected Price to Revenue|Forward P/S Multiple TELO (telomirpharma.com)|RANI - Forward Price-to-Revenue Multiple|SNYR - Price-to-Projected Revenue Ratio|rallybio.com - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP